Last Friday, Luminex Corporation of Austin, Texas announced that it would acquire Tm Bioscience Corp. of Toronto, Ontario. Luminex will pay $44 million, which represents a 41.5% premium for Tm shares based on the December 14 closing price. Tm Bioscience has tests for DNA-based diagnostics, including tests for infectious diseases and genetic mutations related to […]
To access this post, you must purchase The Dark Report.